Thursday, Jan 29 / 2026
Virtual Meeting
  • Thursday, January 29, 2026
  • 09:00 AM - 10:00 AM PST
  • Virtual Only
  • → Join Online
  • Access will be granted upon approval
Download for Outlook/Apple Calendar Add to Google Calendar

DD Call with Pharma in silica

Pharma in silica
Pharma in silica’s precision chemotherapy attacks solid tumors while sparing patients painful, maiming and costly adverse effects imposed by current chemo. OpPacli™ is fifteen months to FDA Phase Ib/IIa 515(b)(2) clinical trial against NSCLC. In 2028, the nanocarrier platform will enable pharmas to capture the chemo drugs US$ 25B market.

Presenting companies:

Pharma in silica
Pharma in silica

Pharma in silica’s precision chemotherapy attacks solid tumors while sparing patients painful, maiming and costly adverse effects imposed by current chemo. OpPacli™ is fifteen months to FDA Phase Ib/IIa 515(b)(2) clinical trial against NSCLC. In 2028, the nanocarrier platform will enable pharmas to capture the chemo drugs US$ 25B market.